A PHASE 1/2 STUDY OF THE SAFETY AND EFFICACY OF ROCILETINIB WHEN ADMINISTERED IN COMBINATION WITH TRAMETINIB IN PATIENTS WITH ACTIVATING EGFR MUTATION-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC):